World-First Lung Cancer Vaccine Trials Launched Across Seven Countries

Doctors have begun trialling the world's first mRNA lung cancer vaccine in patients, as experts hailed its "groundbreaking" potential to save thousands of lives. From a report: Lung cancer is the world's leading cause of cancer death, accounting for about 1.8m deaths every year. Survival rates in those with advanced forms of the disease, where tumours have spread, are particularly poor. Now experts are testing a new jab that instructs the body to hunt down and kill cancer cells -- then prevents them ever coming back. Known as BNT116 and made by BioNTech, the vaccine is designed to treat non-small cell lung cancer (NSCLC), the most common form of the disease. The phase 1 clinical trial, the first human study of BNT116, has launched across 34 research sites in seven countries: the UK, US, Germany, Hungary, Poland, Spain and Turkey. The UK has six sites, located in England and Wales, with the first UK patient to receive the vaccine having their initial dose on Tuesday. Overall, about 130 patients -- from early-stage before surgery or radiotherapy, to late-stage disease or recurrent cancer -- will be enrolled to have the jab alongside immunotherapy. About 20 will be from the UK. The jab uses messenger RNA (mRNA), similar to Covid-19 vaccines, and works by presenting the immune system with tumour markers from NSCLC to prime the body to fight cancer cells expressing these markers. The aim is to strengthen a person's immune response to cancer while leaving healthy cells untouched, unlike chemotherapy.

Read more of this story at Slashdot.